COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01301911
Recruitment Status : Terminated
First Posted : February 23, 2011
Last Update Posted : December 21, 2012
Chinese Academy of Medical Sciences
Information provided by (Responsible Party):
Jiangsu HengRui Medicine Co., Ltd.

Tracking Information
First Submitted Date  ICMJE January 28, 2011
First Posted Date  ICMJE February 23, 2011
Last Update Posted Date December 21, 2012
Study Start Date  ICMJE January 2011
Actual Primary Completion Date November 2012   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 20, 2011)
The maximum-tolerated dose (MTD) regimen of cipatinib will be defined as the maximum dose level at which no more than one subject out of six experiences a dose-limiting toxicity (DLT) after completing one treatment cycle. [ Time Frame: 3 weeks ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 20, 2011)
  • Number of participants with adverse events. [ Time Frame: 6 weeks ]
  • Cipatinib pharmacokinetic parameters may include AUC, Cmax, Tmax, and t1/2. [ Time Frame: 3 weeks ]
  • Objective response rate (ORR). [ Time Frame: 6 weeks ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer
Official Title  ICMJE A Phase I Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer
Brief Summary

Cipatinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. This study is designed to evaluate the safety and tolerability of cipatinib in patients with HER2 positive or uncertain advanced breast cancer:

  1. To evaluate the safety and tolerability of cipatinib, and the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT)
  2. To determine the pharmacokinetic profile of cipatinib and its metabolites
  3. To assess preliminary antitumor activity
  4. To determine preliminary regimen for phase II study
  5. To determine the relation of expression of HER-1 and HER-2 to the antitumor activity.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Breast Cancer
Intervention  ICMJE Drug: Cipatinib
Cipatinib either at 200, 400, 800, 1200, 1400, 1600 or 1800 mg, p.o. once daily
Study Arms  ICMJE Experimental: Cipatinib
Each subject will receive a single dose of cipatinib on treatment day 1, followed by 4-day observation period, and then will receive cipatinib once daily in cycles consisting of 21 days.
Intervention: Drug: Cipatinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: December 20, 2012)
Original Estimated Enrollment  ICMJE
 (submitted: February 20, 2011)
Actual Study Completion Date  ICMJE November 2012
Actual Primary Completion Date November 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Aged ≥ 18 and ≤ 65 years.
  • ECOG performance status of 0 to 1.
  • Life expectancy of more than 3 months.
  • Histologically or cytologic confirmed HER2 positive or uncertain advanced breast cancer that is not curable with available therapies.
  • Screening laboratory values within the following parameters:

    • ANC: ≥ 1.5 x 109/L
    • Platelet count: ≥ 100 x 109/L
    • Hemoglobin: ≥ 9.0 g/dL
    • Serum albumin: ≥ 2.5 g/dL
    • Total bilirubin: ≤ 1.5 x upper limit of normal, ULN
    • ALT and AST: ≤ 1.5 x ULN
    • Serum creatinine: ≤ 1.0 x ULN
    • Creatinie clearnce rate: ≥ 50 mL/min
    • Cholesterol≤7.75 mmol/L and triglyceride≤2.5 x ULN
    • LVEF: ≥ 50%
    • QTcF: < 470 ms
  • Recovery from all clinically significant AEs related to prior therapies. Duration from the latest therapy is more than 6 weeks for nitroso or mitomycin, or more than 4 weeks for operation, radiotherapy, cytotoxic agents or molecular targeting.
  • Ability or willingness to swallow tablets, no dysfunction of gastrointestinal absorption.
  • All subjects who are not surgically sterile or postmenopausal must agree and commit to the use of a reliable method of birth control for the duration of the study and for 6 months after the last dose of test article. For women of child bearing potential, a negative urine or serum pregnancy test result before initiating cipatinib.
  • Signed informed consent.

Exclusion Criteria:

  • Subjects with third space fluid that can not be controled by drainage or other methods.
  • Steroid treatment for more than 50 days, or in need of long-term use of steroids.
  • Subjects with uncontrol hypokalemia and hypomagniesemia before study entry.
  • Subjects can not interrupt the using of the drugs that may cause QT prolongation during study.
  • Subjects with meningioma, or with active central nervous system metastases as indicated by clinical symptoms.
  • Subjects with liver metastases which ALT or AST > 1.5 x ULN.
  • Treated or treating with EGFR or HER2 TKIs before study entry.
  • Receiving any other antitumor therapy.
  • Less than 4 weeks from the last clinical trial.
  • Pregnant or breastfeeding women.
  • Known history of hypersensitivity to cipatinib or any of it components.
  • Ongoing infection (determined by investigator).
  • Subjects had any heart disease: coronary artery disease, arrhythmia need to treat, heart failure, LVEF < 50%, and any other heart disease that is determined as unfit for this study by investigator, etc.
  • Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study. Examples include, but are not limited to, hypertension, severe diabetes, or thyroid disease.
  • Known history of neurological or psychiatric disease, including epilepsy or dementia.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT01301911
Other Study ID Numbers  ICMJE XPTN-Ia-1.0
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Jiangsu HengRui Medicine Co., Ltd.
Study Sponsor  ICMJE Jiangsu HengRui Medicine Co., Ltd.
Collaborators  ICMJE Chinese Academy of Medical Sciences
Investigators  ICMJE Not Provided
PRS Account Jiangsu HengRui Medicine Co., Ltd.
Verification Date December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP